Showing results (111-120 of 264) with videos related to

Sort By:
Pageof 27
Journal of Hematotherapy|November 22, 1997
Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collectionsH M Lazarus, S E Haynesworth, S L Gerson, et al.
Archives of Dermatology|May 1, 1995
Cultures of skin biopsy tissue from immunocompromised patients with cancer and rashesM M Chren, H M Lazarus, R A Salata, et al.
Current Eye Research|July 1, 1993
Antimicrobial activity and in vitro corneal epithelial toxicity of antimicrobial agents for gram-positive corneal pathogensP E Cutarelli, H M Lazarus, M R Jacobs, et al.
Cancer|March 15, 1989
High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia. A phase I-II study of the Southeastern Cancer Study GroupH M Lazarus, W R Vogler, C P Burns, et al.
British Journal of Haematology|July 1, 1993
Defective and normal haematopoietic stem cells in paroxysmal nocturnal haemoglobinuriaL W Terstappen, M Nguyen, S Huang, et al.
Bone Marrow Transplantation|July 5, 2005
Comorbidity indices in hematopoietic stem cell transplantation: a new report cardJ Alamo, M Shahjahan, H M Lazarus, et al.
Bone Marrow Transplantation|February 3, 2009
Are there roles for observational database studies and structured quantification of expert opinion to answer therapy controversies in transplants?R P Gale, M Eapen, B Logan, et al.
Antimicrobial Agents and Chemotherapy|May 1, 1999
Intravenous penciclovir for treatment of herpes simplex infections in immunocompromised patients: results of a multicenter, acyclovir-controlled trial. The Penciclovir Immunocompromised Study GroupH M Lazarus, R Belanger, A Candoni, et al.
Leukemia & Lymphoma|February 27, 1999
Leukemia arising out of paroxysmal nocturnal hemoglobinuriaJ W Harris, R Koscick, H M Lazarus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 1998
Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancerB W Cooper, T J Moss, A A Ross, et al.
Pageof 27